

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/800,350		
		Filing Date	March 12, 2004		
		First Named Inventor	Valery Krasnoperov		
		Art Unit	1642		
		Examiner Name	S. E. Aeder		
Sheet	1	of	1	Attorney Docket Number	VASG-P01-002

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2002/086819	07-04-2002	Drummond et al.	
		2005/0049176	03-03-2005	Kiener et al.	
		2005/0084873	04-21-2005	Krasnoperov et al.	
		2005/0164965	07-28-2005	Reddy et al.	
		2005/0187154	08-25-2005	Kahn et al.	
		2006/0204512	09-14-2006	Krasnoperov et al.	
		2006/0241027	10-26-2006	Hauser et al.	
		2007/0207952	09-06-2007	Silva et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		EP 0.442 724	08-21-1991	Kirin-Amgen, Inc.		
		WO 01/081377	11-01-2001	Amgen, Inc.		
		WO 03/000113	01-03-2003	Genentech Inc		
		WO 04/020468	03-11-2004	Maxygen ApS		
		WO 05/090406	09-29-2005	VasGene Therapeutics, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		BOWIE et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> , Vol. 247(4948), pp. 1306-1310 (1990).	
		BURGESS et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acid fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>Journal of Cell Biology</i> , Vol. 111, pp. 2129-2138 (1990).	
		GOETZ et al., "Long-term serial cultivation of arterial and capillary endothelium from adult bovine brain," <i>In Vitro Cellular and Developmental Biology</i> , 21:172-180 (1985).	
		HE et al., "The Effect of Soluble EphrinB4 Receptor on Laser-Induced Choroidal Neovascularization," <i>IOVS</i> , 45:U804 (2004)	
		NOREN et al., "The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abi-Crk pathway," <i>Nature Cell Bio.</i> 8:815-825 (2006)	
		NOREN et al., "INTERPLAY BETWEEN EphB4 ON TUMOR CELLS AND VASCULAR EPHRIN-B2 REGULATES TUMOR GROWTH," <i>Proceedings of the National Academy of Sciences of USA, National Academy of Science</i> , 101(15):5583-5588 (2004).	
		R&D systems, Recombinant Mouse EphB4/Fc chimera. 11/14/2000, page 1.	
		SEFFERNICK et al., "Melanin Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different," <i>Journal of Bacteriology</i> , Vol. 183(8), pp. 2405-2410 (2001).	
		WANG, H., "Transmembrane Ephrin Ligands in Neural and Vascular Development," <i>DAI</i> , 59(11): 5721 (1999).	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.